Supercharged End-to-Side Anterior Interosseous Nerve Transfer Versus Subcutaneous Ulnar Nerve Transposition for Severe Cubital Tunnel Syndrome: A Comparative Clinical Study.

Authors

Yu Si, Shuang Yang, Lu Ding, Yuannan Peng, ZhengYu Zhang, Xiao Gong, Li Li

Published in

Annals of plastic surgery. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

To compare the clinical and electrophysiological outcomes of subcutaneous ulnar nerve transposition (SCT) alone versus SCT combined with supercharge end-to-side anterior interosseous nerve transfer (SETS) for the treatment of severe cubital tunnel syndrome (CuTS).
This retrospective cohort study included 48 patients with severe CuTS who underwent surgery between 2016 and 2024. Patients were divided into the SETS group (SCT+SETS, n=24) and the control group (SCT alone, n=24). The primary outcome was the rate of recovery of intrinsic hand muscle strength at 12 months postoperatively. Secondary outcomes included compound muscle action potential (CMAP) amplitude, MCV, Quick-DASH scores, SETS-specific near-nerve stimulation positivity rates, and complication rates.
At 12 months postoperatively, 75.0% (18/24) of patients in the SETS group achieved MRC grade 4 first dorsal interosseous (FDI) muscle strength, whereas no control group patient reached grade 4 (P<0.001). SETS group FDI-CMAP amplitude improved from 0.58±0.12 mV preoperatively to 2.45±0.85 mV postoperatively, with a mean improvement of 1.87±0.79 mV, significantly greater than the 0.70±0.78 mV improvement in the control group (P<0.001). The near-nerve stimulation positivity rate in the SETS group was 71.4%. Complication rates did not differ significantly between groups (P>0.05). Multivariate logistic regression identified disease duration <12 months (OR=4.2, 95% CI: 1.6-11.0), preoperative FDI strength ≥MRC grade 2 (OR=3.5, 95% CI: 1.3-9.4), and age <60 years (OR=2.7, 95% CI: 1.0-7.2) as independent predictors of favorable functional recovery after SETS.
In patients with severe CuTS, adding SETS to SCT significantly improves intrinsic hand muscle strength recovery and electrophysiological outcomes without increasing the risk of complications. Patients with disease duration <12 months, age <60 years, and mild-to-moderate preoperative muscle atrophy derive the greatest benefit.

PMID:
42842816
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.